YOLO: 2nd Quarter 2026 Portfolio Review

Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. For the fund’s most recent standardized and month-end performance, please click www.advisorshares.com/etfs/yolo.

Portfolio

Performance

The AdvisorShares Pure Cannabis ETF (YOLO) returned +9.08% (NAV) / +9.51% (market) in Q2 2026, recovering a portion of the ground lost in the first quarter as global cannabis sentiment improved alongside the U.S. federal rescheduling news. The S&P 500 Index returned +15.20% over the same three-month period.

Portfolio

YOLO continued its active management approach through the second quarter, including a continued shift in how the portfolio gains exposure to certain underlying names. Historically, a meaningful portion of YOLO‘s U.S. multi-state operator exposure has come indirectly through its position in the affiliated fund MSOS, which in turn holds some names via total return swap rather than direct stock ownership. During the quarter, YOLO continued rotating a portion of that indirect exposure into direct, listed positions in select underlying companies — reducing swap-based exposure where a name is directly tradable and building out YOLO’s own line item in that stock, while maintaining its core allocation to MSOS.

This is part of a longer-term effort to build YOLO into a more globally diversified, directly-held portfolio over time, reducing reliance on affiliated fund swap structures where listed alternatives exist. This transition is ongoing and YOLO‘s exposure to U.S. multi-state operators will likely continue to reflect a mix of direct holdings and indirect exposure through MSOS for the foreseeable future.

The portfolio continues to emphasize operators with strong balance sheets, diversified revenue, and meaningful exposure to maturing regulatory markets globally.

Winners and Losers

Names that stood out on the upside this quarter included:

  • AdvisorShares Pure US Cannabis ETF (MSOS): +42.16%
  • Curaleaf Holdings Inc. (CURLF): +8.91%

On the other end of the spectrum, the following names weighed most heavily on returns:

  • Village Farms International Inc. (VFF): -29.58%
  • Charlottes Web Holdings Inc. (CWEB): -56.72%

Top Holdings

Ticker Security Description Portfolio Weight %
MSOS ADVISORSHARES PURE US CANN 22.96%
CURLF CURALEAF HOLDINGS INC 15.15%
TRLV TRULIEVE CANNABIS CORP 13.09%
VFF VILLAGE FARMS INTERNATIONAL 10.54%
HITI HIGH TIDE INC 7.86%
CRON CRONOS GROUP INC 3.91%
GLAS GLASS HOUSE BRANDS INC 3.79%
CWEB CHARLOTTES WEB HOLDINGS INC 2.74%
OGI ORGANIGRAM GLOBAL INC 2.64%
TSNDF TERRASCEND CORP 2.57%

As of 06.30.2026. Cash is not included. Subject to change.

Please see our complete Fund holdings at advisorshares.com/etfs/yolo. The holdings details are updated each market day.

International Cannabis Landscape

The second quarter of 2026 was dominated by developments in the United States, where the Department of Justice issued a final order on April 23, 2026, immediately reclassifying state-licensed medical cannabis, and cannabis contained in FDA-approved drug products, from Schedule I to Schedule III. A separate, broader DEA administrative hearing on full rescheduling of cannabis began June 29, 2026, and continues into the current quarter, alongside ongoing legal challenges to the April order at the D.C. Circuit.

Internationally, Canadian and European trade dynamics continued largely along their established path, with Germany’s partial legalization framework sustaining demand for EU GMP-certified Canadian supply, and Australia’s therapeutic cannabis market continuing its gradual maturation.

Outlook

As we move into Q3 2026, YOLO’s global exposure continues to provide access across maturing international markets. For the U.S. portion of the portfolio, the DEA’s administrative hearing on broader federal rescheduling and the pending D.C. Circuit litigation related to the April order remain the most consequential near-term developments to monitor. These proceedings may also set precedent for policymakers and market participants outside the United States as other countries evaluate their own cannabis frameworks. We will continue to actively manage the fund as regulatory, legal, and market conditions evolve across its global opportunity set.

Sources:
1. Marijuana Policy Project. DOJ Reschedules State-Legal Medical Cannabis to Schedule III: Questions and Answers. 2026.
2. Foley Hoag LLP. DOJ Immediately Reschedules State-Licensed Medical Cannabis to Schedule III — and Restarts the Clock on Broader Rescheduling. April 23, 2026.
3. Ropes & Gray LLP. Clearing the Haze? Federal Marijuana Rescheduling Heads to DEA Hearing as Legal Challenges Loom. 2026.

——————————————————————-

Tune in to AdvisorShares’ Alpha Nooner Show streaming live each regular weekday starting at 12:00 pm (East Coast time), where I am a guest almost every Tuesday. Find it on most major social media platforms or visit our the AdvisorShares “Events” webpage for more information.

Dan Arens​Cheers,

Dan Ahrens
AdvisorShares
AdvisorShares Pure Cannabis ETF (YOLO) Portfolio Manager

Past Commentary

Definitions 

EU-GMP stands for European Union Good Manufacturing Practice. This standard means that a product, typically a pharmaceutical, medicine, or active pharmaceutical ingredient (API), has been manufactured, tested, and packaged according to the strict quality standards set by the European Union.

Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus or summary prospectus, a copy of which may be obtained by visiting www.advisorshares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor.

The Fund is subject to a number of risks that may affect the value of its shares. This section provides additional information about the Fund’s principal risks. The degree to which a risk applies to the Fund varies according to its investment allocation. Each investor should review the complete description of the principal risks before investing in the Fund. As with investing in other securities whose prices increase and decrease in market value, you may lose money by investing in the Fund.

Cannabis-Related Company Risk. Cannabis-related companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may (i) significantly affect a cannabis-related company’s ability to secure financing, (ii) impact the market for marijuana industry sales and services, and (iii) set limitations on marijuana use, production, transportation, and storage. Cannabis-related companies may also be required to secure permits and authorizations from government agencies to cultivate or research marijuana. In addition, cannabis-related companies are subject to the risks associated with the greater agricultural industry, including changes to or trends that affect commodity prices, labor costs, weather conditions, and laws and regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and patents, technological change and obsolescence, product liability lawsuits, and the risk that research and development may not necessarily lead to commercially successful products.

Shares are bought and sold at market price (closing price) not NAV and are not individually redeemed from the Fund. Market price returns are based on the midpoint of the bid/ask spread at 4:00 pm Eastern Time (when NAV is normally determined), and do not represent the return you would receive if you traded at other times.

Holdings and allocations are subject to risks and to change.

The views in this commentary are those of the portfolio manager and may not reflect his views on the date this material is distributed or any time thereafter. These views are intended to assist shareholders in understanding their investments and do not constitute investment advice.